Abstract
Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the outcome of therapy and of the development of comorbidities. In this review we aimed to evaluate the relationship between plasma total antioxidant capacity (TAC) and peroxidation biomarkers, as well as their association with dyslipidemia and systemic inflammation in psoriasis. The review of 59 case–control comparisons (from 41 studies) and 17 interventions (from 13 studies) suggests that peroxidation markers are more sensitive than TAC in the evaluation of oxidative stress in psoriasis. Although few studies investigated the effect of treatment on oxidative stress, it seems that biological drugs could be the better choice in the treatment of psoriasis. However, considering the limitations of TAC and plasma peroxidation markers, this review suggests that new methods should be developed in order to evaluate systemic oxidative stress in psoriasis.
Highlights
IntroductionBiomarkers could be relevant for distinction between the different clinical variants of the disease, for the assessment of disease activity and severity and for the prediction of the outcome of a therapeutic intervention [1, 2]
Psoriasis is a common, chronic inflammatory and immune-mediated skin disease [1, 2].In psoriatic patients, biomarkers could be relevant for distinction between the different clinical variants of the disease, for the assessment of disease activity and severity and for the prediction of the outcome of a therapeutic intervention [1, 2]
Overall the reviewed case–control (Table 1) and intervention (Table 2) studies suggest that peroxidation markers are more sensitive than total antioxidant capacity (TAC) in the evaluation of oxidative stress in psoriasis (Fig. 1)
Summary
Biomarkers could be relevant for distinction between the different clinical variants of the disease, for the assessment of disease activity and severity and for the prediction of the outcome of a therapeutic intervention [1, 2]. The great importance of the use of biomarkers for the prediction of the development of comorbidities such as arthritis, cardiovascular diseases (CVD) and metabolic syndrome has been acknowledged [3,4,5,6,7]. Soluble biomarkers have the potential to be useful for screening patients with psoriasis for underlying psoriatic arthritis [2]. The initial inflammatory events originate in the plaque (activation of monocytoid dendritic cells, macrophages and T cells) and lead to an increase of tumor necrosis factor alpha (TNF-α) production.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
